THL employees are eager to put their intelligence, energy and enthusiasm to work in a culture that’s hard to match.”

As a Vice President of Investor Relations, Sam provides best-in-class client service to existing and prospective limited partners (LPs). She works closely with the firm’s legal, finance and investment professionals on both the co-investment syndication process and portfolio analysis.

Before joining the THL team, Sam worked at HarbourVest Partners. Outside the office, she loves playing tennis, snowboarding and being on the water. 

Related content

Forward Through Uncertainty: What Biopharma Leaders Are Saying About the FDA, R&D Investment
Insights
Forward Through Uncertainty: What Biopharma Leaders Are Saying About the FDA, R&D Investment 

Key Takeaways Recent FDA changes have generated uncertainty across the biopharma sector, with questions mounting around approval timelines, shifting trial expectations, and regulatory consistency. In May and June 2025, THL surveyed 100 biopharma decision-makers—spanning early-stage biotechs to top 50 pharma companies—to better understand how today’s regulatory and market dynamics are influencing R&D investment. Most respondents plan to maintain

Healthcare (HC)
Navigating Uncertainty, Unlocking Growth: Why Middle Market Companies Need a Strategic Capital Markets Approach
Insights
Navigating Uncertainty, Unlocking Growth: Why Middle Market Companies Need a Strategic Capital Markets Approach 

THL in Action In today’s uncertain macroeconomic environment, middle market companies face a complex financial puzzle: how to achieve growth while managing higher interest costs, preserving flexibility, mitigating risk, and navigating dynamic and rapidly evolving credit markets. For businesses looking to invest in new products, expand into adjacent markets, build and upscale critical IT infrastructure, or

Automation